- Genentech's investment in Holly Springs facility increases to $2 billion.
- The facility will be operational by 2029, focusing on treatments for metabolic conditions.
- The expansion supports over 2,000 jobs, including 500+ manufacturing and 1,500+ construction roles.
- This project is part of Roche and Genentech's $50 billion U.S. manufacturing commitment.
Investment Expansion
Genentech, part of the Roche Group, has announced an increase in its investment for the Holly Springs, North Carolina manufacturing facility, raising the total to approximately $2 billion. This expansion is part of Roche and Genentech's broader $50 billion commitment to U.S. manufacturing and R&D.
Facility Development
Construction of the state-of-the-art biomanufacturing facility began in August 2025, with operations expected to commence by 2029. The facility will focus on producing next-generation treatments for metabolic conditions, such as obesity, utilizing advanced biomanufacturing, automation, and digital tools to enhance efficiency and sustainability.
Economic Impact
The investment is projected to support over 2,000 jobs, including more than 500 high-wage manufacturing positions and 1,500 construction jobs. This development underscores Genentech's role as a significant economic driver in the region.
Strategic Location
Holly Springs was chosen for its skilled local workforce, strong academic institutions, and proximity to other life science companies in the Raleigh-Durham area. The expansion aligns with Genentech's goal to strengthen domestic production and innovation in the U.S.
